31 August 2022 false No description of principal activity Taxfiler 2023.15 14327803business:PrivateLimitedCompanyLtd2022-08-312023-08-31 143278032022-08-30 143278032022-08-312023-08-31 14327803business:AuditExempt-NoAccountantsReport2022-08-312023-08-31 14327803business:FilletedAccounts2022-08-312023-08-31 143278032023-08-31 14327803business:Director12022-08-312023-08-31 14327803business:Director22022-08-312023-08-31 14327803business:RegisteredOffice2022-08-312023-08-31 14327803core:WithinOneYear2023-08-31 14327803core:AfterOneYear2023-08-31 14327803core:ShareCapitalcore:PreviouslyStatedAmount2023-08-31 14327803core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-08-31 14327803core:PreviouslyStatedAmount2023-08-31 14327803business:SmallEntities2022-08-312023-08-31 14327803countries:EnglandWales2022-08-312023-08-31 14327803core:ComputerEquipment2022-08-312023-08-31 14327803core:Goodwill2022-08-30 14327803core:Goodwill2022-08-312023-08-31 14327803core:Goodwill2023-08-31 14327803core:ComputerEquipment2022-08-30 14327803core:ComputerEquipment2023-08-31 iso4217:GBP xbrli:pure
Company Registration No. 14327803 (England and Wales)
Weymouth Pharma Ltd Unaudited accounts for the period from 31 August 2022 to 31 August 2023
Weymouth Pharma Ltd Unaudited accounts Contents
Page
- 2 -
Weymouth Pharma Ltd Company Information for the period from 31 August 2022 to 31 August 2023
Directors
Sunil Varghese Chacko Moyosoreoluwa Ogunfowoke
Company Number
14327803 (England and Wales)
Registered Office
19 Fuchsia Gardens Southampton SO16 6TY United Kingdom
- 3 -
Weymouth Pharma Ltd Statement of financial position as at 31 August 2023
2023 
Notes
£ 
Fixed assets
Intangible assets
233,094 
Tangible assets
4,280 
237,374 
Current assets
Inventories
81,500 
Debtors
59,983 
Cash at bank and in hand
30,733 
172,216 
Creditors: amounts falling due within one year
(227,265)
Net current liabilities
(55,049)
Total assets less current liabilities
182,325 
Creditors: amounts falling due after more than one year
(181,210)
Net assets
1,115 
Capital and reserves
Called up share capital
100 
Profit and loss account
1,015 
Shareholders' funds
1,115 
For the period ending 31 August 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 4 April 2024 and were signed on its behalf by
Sunil Varghese Chacko Director Company Registration No. 14327803
- 4 -
Weymouth Pharma Ltd Notes to the Accounts for the period from 31 August 2022 to 31 August 2023
1
Statutory information
Weymouth Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 14327803. The registered office is 19 Fuchsia Gardens, Southampton, SO16 6TY, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
20% reduce balance basis
4
Intangible fixed assets
Goodwill 
£ 
Cost
At 31 August 2022
- 
Additions
237,045 
At 31 August 2023
237,045 
Amortisation
At 31 August 2022
- 
Charge for the period
3,951 
At 31 August 2023
3,951 
Net book value
At 31 August 2023
233,094 
- 5 -
Weymouth Pharma Ltd Notes to the Accounts for the period from 31 August 2022 to 31 August 2023
5
Tangible fixed assets
Computer equipment 
£ 
Cost or valuation
At cost 
At 31 August 2022
- 
Additions
5,350 
At 31 August 2023
5,350 
Depreciation
Charge for the period
1,070 
At 31 August 2023
1,070 
Net book value
At 31 August 2023
4,280 
6
Debtors
2023 
£ 
Amounts falling due within one year
VAT
21,864 
Trade debtors
38,119 
59,983 
7
Creditors: amounts falling due within one year
2023 
£ 
Trade creditors
44,312 
Taxes and social security
1,247 
Other creditors
9,982 
Loans from directors
171,524 
Accruals
200 
227,265 
8
Creditors: amounts falling due after more than one year
2023 
£ 
Bank loans
181,210 
9
Average number of employees
During the period the average number of employees was 4.
- 6 -